Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation

Bone Marrow Transplantation
Irit AviviS Mackinnon

Abstract

We report the incidence, characteristics and outcome of neurological complications occurring following reduced-intensity conditioning (RIC) in 85 patients who received a related/unrelated donor stem cell transplantation following therapy with alemtuzumab, fludarabine and melphalan. Six patients (probability 8.9%) developed severe neurological complications at a median of 151 days (24-334 days). Five of them presented with progressive peripheral sensori-motor radiculo-neuropathy and/or myelitis, preceded by one or more viral reactivation/infection. Despite treatment with immunoglobulins/plasmapheresis/steroids, four died of respiratory failure due to progressive peripheral neurophathy. Viral infection was identified as the only risk factor for the development of neurological complications. Patients who are treated with alemtuzumab-based RIC may have a lower risk of developing regimen-related neurological complications, but are more susceptible to develop peripheral radiculo-neuropathy or myelitis. This phenomenon may be possibly related to viral infection associated with delayed immunological recovery or immunological dysregulation caused by alemtuzumab-induced T-cell depletion.

References

Nov 23, 1995·The New England Journal of Medicine·J H ReesR A Hughes
Jan 1, 1995·Pediatric Neurology·C AdamsJ T Sladky
Aug 1, 1994·Journal of the Neurological Sciences·W LiedtkeU W Schaefer
May 23, 1998·Journal of the Neurological Sciences·N Yuki, Y Tagawa
Feb 16, 2000·Bone Marrow Transplantation·L F Bleggi-TorresC R de Medeiros
Aug 18, 2001·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C SolaroA Uccelli
Oct 18, 2001·Current Opinion in Hematology·P J MedinaJ N George
Nov 29, 2001·Molecular Pathology : MP·J B Winer

❮ Previous
Next ❯

Citations

Mar 22, 2013·Drugs·Eduardo Nobile-Orazio, Francesca Gallia
Apr 6, 2007·Nature Clinical Practice. Neurology·Gerd Meyer zu HörsteBernd C Kieseier
May 18, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·C HirstN Robertson
Jan 26, 2007·Expert Opinion on Biological Therapy·Lakshmanan Krishnamurti
Mar 24, 2010·Pediatric Clinics of North America·Frans J SmiersGuido Lucarelli
Apr 29, 2009·Annals of Neurology·Joseph R Berger, Sidney Houff
Jul 1, 2014·Journal of the Peripheral Nervous System : JPNS·Guido Cavaletti
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Pere BarbaJorge Sierra
Sep 14, 2006·Current Opinion in Neurology·Bernd C KieseierHans-Peter Hartung
Aug 29, 2013·The Neurohospitalist·Amy A PruittMyrna R Rosenfeld
Jul 19, 2011·Journal of Intensive Care Medicine·Aliaksei PustavoitauRobert Stevens
May 21, 2015·American Society of Clinical Oncology Educational Book·Guido CavalettiPaola Marmiroli
Apr 18, 2020·Neurology. Neuroimmunology and Neuroinflammation·Marieke van der ZwanBart C Jacobs
Jan 23, 2021·Journal of Nephrology·Irene FaravelliClaudio Ponticelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.